Par Pharmaceutical Companies | Evaluate

Private equity cleans up Sanofi’s failed generics foray

October 04, 2016

Debt binge sees Aralez become a mini-Valeant

January 14, 2016

Pfallergan rewrites the takeover record books

July 15, 2015

M&A keeps up feverish pace in first half of 2015

May 26, 2015

Speciality players define M&A as big pharma seeks focus

May 18, 2015

Endo the story for Par

July 17, 2012

Private equity looks to shoot level Par with $1.9bn bid

March 30, 2011

Pronova's compromise with Apotex a step in the right direction

March 28, 2011

Event - Lovaza patent trial crucial to halt Pronova's bad run

April 15, 2010

Santarus suffers heartburn from Zegerid patent loss

April 06, 2010

Sanofi's Eloxatin pact could join FTC's pay-for-delay tally

Load More